The center, based in the eastern Hangzhou region, is the New York-based drug company’s first biotech center in Asia.
The facility, expected to be completed by 2018, will develop biologic drugs and lower-cost biosimilars. Pfizer plans to work closely with local regulators to bring the drugs to market as soon as possible, according to a statement on its website.
Pfizer’s plans depict a recent trend by pharma industry giants to develop new strategies to tap into China’s healthcare market, which is estimated to be around $185 billion by 2018.
More articles on supply chain:
Leukocyte reduction devices recalled for faulty filters
5 latest FDA approvals
Medtronic acquires HeartWare for $1.1B
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
